Yuichiro Iwamoto, Shuhei Nakanishi, Masahiro Komi, Yuto Kimura, Yuki Watanabe, Taku Sasaki, Erina Nakao, Masato Kubo, Toshitomo Sugisaki, Kazunori Dan, Yui Okamoto, Hideyuki Iwamoto, Junpei Sanada, Yoshiro Fushimi, Yukino Katakura, Tomohiko Kimura, Masashi Shimoda, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Recommendation from the Editor in Chief
There are examples where distinct two peptide ligands respectively act as an agonist and antagonist on the same receptor. To my knowledge, the best-known one is related with the story that alpha-MSH and agouti-related peptide (AgRP) act on the melanocrtin-4 receptor (MC4R) as an agonist and antagonist, thereby minutely regulating appetite and body weight. In this issue, Dr. Katsuya Sakai and Professor Masamitsu Nakazato, a world-renowned physician scientist on research of orexigenic hormone ghrelin, provide us with well-organized, fabulous review article focusing on the dynamic interaction between ghrelin and LEAP-2 (liver-expressed antimicrobial peptide 2) in terms of stomach-liver axis-driven appetite control. Indeed, ghrelin and LEAP-2 respectively act as an agonist and antagonist on the same receptor, GHSR (growth hormone secretagogue receptor). Our editorial team has a firm belief that all readers are surely motivated by the real deal of authentic endocrinology and cutting-edge medicine on GPCR signal transduction in this article.